Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Beat The Street With SI Traders -- Ignore unavailable to you. Want to Upgrade?

To: heinz44 who wrote (112988)	5/29/2013 10:45:30 AM
From: El Canadiense	Respond to of 233880

dont wait too much ...

To: heinz44 who wrote (112988)	5/29/2013 10:49:42 AM
From: El Canadiense	Read Replies (1) \| Respond to of 233880

Apricus Biosciences Buy limit: $3 The market for erectile dysfunction drugs is huge. Men forked out $3.93 billion for Viagra and Cialis alone last year. But not everyone can use these drugs. They don't mix with certain heart medications or alcohol. They have potential side effects like the "blue halo" that can affect the vision of Viagra users. And some guys would rather not have to wait the time it takes for them to kick in. Enter Apricus Biosciences ( APRI), a tiny biotech with big potential andan alternative called Vitaros. The drug should hit the market soon in Canada, where Apricus has partnered withAbbott Laboratories ( ABT). Apricus expects approval in Europe by the end of June. It already has partnered with big pharma companies to sell in England, Germany and Italy. More deals will follow on better terms after approval, predicts Steven Schuster, a value manager at Bridge Street Asset Management, which owns the stock. I think Schuster is worth listening to because he suggested Global Ship Lease ( GSL) for my under $5 stock column last March when it was around $2.50. Global Ship Lease has almost doubled, to $4.60, since (and it has further to go, by the way). Apricus' Vitaros is a cream that delivers alprostadil, which increases blood flow to the penis. The company says Vitaros works because its NexACT drug delivery technology helps the drug pass through the skin. Apricus also has a second product that the company thinks can treat "female sexual arousal disorder." Called Femprox, it delivers the same substance as the one in Vitaros, but at a slightly higher dose. Femprox still being tested. Lazard Capital Markets analyst William Tanner has an $8 price target on the stock.